Indivi, a leading MedTech firm based in Basel, Switzerland, has recently partnered with Biogen to propel the advancement of digital health technology and the development of digital biomarkers tailored for Parkinson's disease. This collaboration involves Biogen licensing KonectomTM, a smartphone-based digital biomarker platform, to Indivi. KonectomTM enables remote assessment of neurological functions, allowing for more precise and frequent monitoring of Parkinson's disease progression.

As part of the agreement, Indivi will oversee the digital management of KonectomTM in the Phase 2b LUMA study, which evaluates BIIB122's efficacy and safety in early-stage Parkinson's disease patients. The study is conducted in collaboration with Denali Therapeutics Inc. Indivi's responsibilities include maintaining the deployment of KonectomTM, ongoing service provision, algorithm development, and data processing to derive digital metrics from the LUMA study.

Additionally, both Biogen and Indivi plan to collaborate on developing and validating novel digital endpoints for Parkinson's disease, as well as exploring other disease areas for endpoint development utilizing KonectomTM. Given the lack of disease-modifying treatments for Parkinson's disease and the limitations of current subjective clinical measurement tools, this partnership holds significant promise.

Indivi utilizes advanced computational and statistical modeling techniques to enhance the precision of Parkinson's disease progression measures, aiming to overcome existing challenges. Furthermore, by integrating KonectomTM with dreaMSMD, a digital biomarker platform designed for individuals with multiple sclerosis, Indivi aims to offer a comprehensive digital measurement solution covering key neurological areas.

Source: businesswire.com